Ab­b­Vie nabs sev­enth FDA ap­proval for Rin­voq, adds Crohn’s dis­ease in­di­ca­tion

Ab­b­Vie picked up an­oth­er in­di­ca­tion for block­buster Rin­voq on Thurs­day, this time for Crohn’s dis­ease. The sev­enth FDA ap­proval for the JAK in­hibitor is specif­i­cal­ly for use in mod­er­ate to se­vere Crohn’s pa­tients who have had in­ad­e­quate re­sponse or in­tol­er­ance of at least one TNF block­er.

While there are sev­er­al oth­er bi­o­log­ics al­ready on the mar­ket to treat mod­er­ate­ly to se­vere­ly ac­tive Crohn’s in­clud­ing J&J’s Ste­lara, Take­da’s En­tyvio and Ab­b­Vie’s own Skyrizi, the FDA not­ed that Rin­voq is the first oral drug.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN